Blog
Discover expert articles and perspectives on diagnosing and monitoring multiple myeloma, as well as insights into immune system disorders
Featured
Monoclonal protein testing enters a new era at ADLM 2026
Explore how mass spectrometry is reshaping monoclonal protein detection at ADLM 2026. Visit The Binding Site to see live EXENT demos.
Learn more
The sensitivity gap that launched a platform
Learn more
Challenges of running special protein tests on automated lines
Learn more
New perspectives on monoclonal proteins
Learn more
Challenges of running special protein tests on automated lines
Special protein assays have requirements that can slow automated chemistry lines, increase manual steps, and affect turnaround times, maintenance, and reliability.
Read more
Monoclonal protein testing enters a new era at ADLM 2026
Explore how mass spectrometry is reshaping monoclonal protein detection at ADLM 2026. Visit The Binding Site to see live EXENT demos.
Read more
The sensitivity gap that launched a platform
~45% of myeloma patients in complete response still carry M-protein detectable by mass spectrometry. How EXENT made that research insight routinely actionable.
Read more
Celebrating 30 Years of Innovation at EHA2025
Celebrating 30 Years of Innovation at EHA2025 - event recap
Read more
New perspectives on monoclonal proteins
Advancing diagnostic confidence with the EXENT® System
Read more
Advancing protein diagnostics through scientific leadership
The Binding Site advances protein diagnostics through scientific leadership and innovation to address unmet needs in multiple myeloma and immune disorders.
Read more
Understanding light chains and the importance of sFLC testing in multiple myeloma
Light chains play a key role in myeloma. Learn how sFLC tests help assess their levels and ratios, aiding diagnosis and treatment decisions.
Read more